Progress and Challenges in the Development of COVID-19 Vaccines and Current Understanding of SARS-CoV-2- Specific Immune Responses

키워드

참고문헌 (69)

1. Zhou P, "A pneumonia outbreak associated with a new coronavirus of probable bat origin", Nature, 579, pp.270~273 (2020)
2. Zumla A, "Coronaviruses-drug discovery and therapeutic options", Nat. Rev. Drug Discov, 15, pp.327~347 (2016)
3. Cheng VC, "Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection", Clin. Microbiol. Rev, 20, pp.660~694 (2007)
4. Chan JF, "Middle East respiratory syndrome coronavirus : another zoonotic betacoronavirus causing SARS-like disease", Clin. Microbiol. Rev, 28, pp.465~522 (2015)
5. 이정윤, "Middle East Respiratory Syndrome Coronavirus-Encoded Accessory Proteins Impair MDA5-and TBK1-Mediated Activation of NF-κB", Journal of Microbiology and Biotechnology, 29(8), pp.1316~1323 (2019), 한국미생물·생명공학회[DOI]
6. Gralinski LE, "Molecular pathology of emerging coronavirus infections", J. Pathol, 235, pp.185~195 (2015)
7. Velavan TP, "The COVID-19 epidemic", Trop. Med. Int. Health, 25, pp.278~280 (2020)
8. Lake MA, "What we know so far : COVID-19 current clinical knowledge and research", Clin. Med(Lond), 20, pp.124~127 (2020)
9. Guan WJ, "Clinical characteristics of Coronavirus disease 2019 in China", N. Engl. J. Med, 382, pp.1708~1720 (2020)
10. Li Q, "Early transmission dynamics in Wuhan, China, of novel Coronavirus-Infected pneumonia", N. Engl. J. Med, 382, pp.1199~1207 (2020)
11. Prompetchara E, "Immune responses in COVID-19 and potential vaccines : Lessons learned from SARS and MERS epidemic", Asian Pac. J. Allergy Immunol, 38, pp.1~9 (2020)
12. Cucinotta D, "WHO declares COVID-19 a pandemic", Acta Biomed, 91, pp.157~160 (2020)
13. Lu S, "Timely development of vaccines against SARS-CoV-2", Emerg. Microbes Infect, 9, pp.542~544 (2020)
14. 이정윤, "Generation of Full-Length Infectious cDNA Clones of Middle East Respiratory Syndrome Coronavirus", Journal of Microbiology and Biotechnology, 29(6), pp.999~1007 (2019), 한국미생물·생명공학회[DOI]
15. Jiang S, "SARS vaccine development", Emerg. Infect. Dis, 11, pp.1016~1020 (2005)
16. Yong CY, "Recent advances in the vaccine development against Middle East respiratory syndrome-coronavirus", Front. Microbiol, 10, pp.1781~ (2019)
17. Lin JT, "Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine", Antivir. Ther, 12, pp.1107~1113 (2007)
18. Martin JE, "A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial", Vaccine, 26, pp.6338~6343 (2008)
19. Modjarrad K, "Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine : a phase 1, open-label, single-arm, dose-escalation trial", Lancet Infect. Dis, 19, pp.1013~1022 (2019)
20. Ahmed SF, "Preliminary identification of potential vaccine targets for the COVID-19 Coronavirus(SARS-CoV-2)based on SARS-CoV immunological studies", Viruses, 12, pp.254~ (2020)
21. Dhama K, "COVID-19, an emerging coronavirus infection : advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics", Hum. Vaccin. Immunother, 16, pp.1232~1238 (2020)
22. Lu R, "Genomic characterisation and epidemiology of 2019 novel coronavirus : implications for virus origins and receptor binding", Lancet, 395, pp.565~574 (2020)
23. Wrapp D, "Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation", Science, 367, pp.1260~1263 (2020)
24. Yan R, "Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2", Science, 367, pp.1444~1448 (2020)
25. Zhou Y, "Prospects for a MERS-CoV spike vaccine", Expert Rev. Vaccines, 17, pp.677~686 (2018)
26. Koyama S, "Innate immune response to viral infection", Cytokine, 43, pp.336~341 (2008)
27. Thompson MR, "Pattern recognition receptors and the innate immune response to viral infection", Viruses, 3, pp.920~940 (2011)
28. Teijaro JR, "Type I interferons in viral control and immune regulation", Curr. Opin. Virol, 16, pp.31~40 (2016)
29. Jensen S, "Sensing of RNA viruses : a review of innate immune receptors involved in recognizing RNA virus invasion", J. Virol, 86, pp.2900~2910 (2012)
30. He L, "Expression of elevated levels of pro-inflammatory cytokines in SARS-CoVinfected ACE2+ cells in SARS patients : relation to the acute lung injury and pathogenesis of SARS", J. Pathol, 210, pp.288~297 (2006)
31. Perlman S, "Immunopathogenesis of coronavirus infections : implications for SARS", Nat. Rev. Immunol, 5, pp.917~927 (2005)
32. Zumla A, "Middle East respiratory syndrome", Lancet, 386, pp.995~1007 (2015)
33. Snijder EJ, "Ultrastructure and origin of membrane vesicles associated with the severe acute respiratory syndrome coronavirus replication complex", J. Virol, 80, pp.5927~5940 (2006)
34. Blanchard E, "Virus-induced double-membrane vesicles", Cell. Microbiol, 17, pp.45~50 (2015)
35. Haller O, "Interferon-induced mx proteins : dynamin-like GTPases with antiviral activity", Traffic, 3, pp.710~717 (2002)
36. Sen GC, "Viruses and interferons", Annu. Rev. Microbiol, 55, pp.255~281 (2001)
37. Kurche JS, "Type I IFN-dependent T cell activation is mediated by IFNdependent dendritic cell OX40 ligand expression and is independent of T cell IFNR expression", J. Immunol, 188, pp.585~593 (2012)
38. 이정윤, "Middle East Respiratory Syndrome Coronavirus-Encoded ORF8b Inhibits RIG-I-Like Receptors by a Differential Mechanism", Journal of Microbiology and Biotechnology, 29(12), pp.2014~2021 (2019), 한국미생물·생명공학회[DOI]
39. Jeong Yoon Lee, "Middle East respiratory syndrome coronavirus-encoded ORF8b strongly antagonizes IFN-β promoter activation: its implication for vaccine design", The Journal of Microbiology, 57(9), pp.803~811 (2019), 한국미생물학회[DOI]
40. Lokugamage KG, "SARS-CoV-2 sensitive to type I interferon pretreatment", bioRxiv 2020.2003.2007.982264, ~ (2020)
41. Team CC-R, "Severe outcomes among patients with Coronavirus Disease 2019(COVID-19)-United States, February 12-March 16, 2020", MMWR Morb Mortal Wkly Rep, 69, pp.343~346 (2020)
42. Shaw AC, "Age-dependent dysregulation of innate immunity", Nat. Rev. Immunol, 13, pp.875~887 (2013)
43. Li T, "Significant changes of peripheral T lymphocyte subsets in patients with severe acute respiratory syndrome", J. Infect. Dis, 189, pp.648~651 (2004)
44. Xie J, "Dynamic changes of T lymphocyte subsets in the long-term follow-up of severe acute respiratory syndrome patients", Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 28, pp.253~255 (2006)
45. Chen J, "Clinical progression of patients with COVID-19 in Shanghai, China", J. Infect, 80, pp.e1~e6 (2020)
46. Qin C, "Dysregulation of immune response in patients with COVID-19 in Wuhan, China", Clin. Infect. Dis, 71, pp.762~768 (2020)
47. Zheng HY, "Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients", Cell. Mol. Immunol, 17, pp.541~543 (2020)
48. Channappanavar R, "Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice", Cell Host Microbe, 19, pp.181~193 (2016)
49. Snell LM, "Overcoming CD4 Th1 cell fate restrictions to sustain antiviral CD8 T cells and control persistent virus infection", Cell. Rep, 16, pp.3286~3296 (2016)
50. Wong CK, "Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome", Clin. Exp. Immunol, 136, pp.95~103 (2004)
51. Mahallawi WH, "MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile", Cytokine, 104, pp.8~13 (2018)
52. Huang C, "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China", Lancet, 395, pp.497~506 (2020)
53. McElroy AK, "Human Ebola virus infection results in substantial immune activation", Proc. Natl. Acad. Sci. USA, 112, pp.4719~4724 (2015)
54. Thevarajan I, "Breadth of concomitant immune responses prior to patient recovery : a case report of non-severe COVID-19", Nat. Med, 26, pp.453~455 (2020)
55. Tisoncik JR, "Into the eye of the cytokine storm", Microbiol. Mol. Biol. Rev, 76, pp.16~32 (2012)
56. Newton AH, "The host immune response in respiratory virus infection : balancing virus clearance and immunopathology", Semin. Immunopathol, 38, pp.471~482 (2016)
57. Ababneh M, "Recombinant adenoviral vaccine encoding the spike 1 subunit of the Middle East Respiratory Syndrome Coronavirus elicits strong humoral and cellular immune responses in mice", Vet. World, 12, pp.1554~1562 (2019)
58. Li G, "Coronavirus infections and immune responses", J. Med. Virol, 92, pp.424~432 (2020)
59. Li G, "Profile of specific antibodies to the SARS-associated coronavirus", N. Engl. J. Med, 349, pp.508~509 (2003)
60. Cheng M, "Cross-reactivity of antibody against SARS-coronavirus nucleocapsid protein with IL-11", Biochem. Biophys. Res. Commun, 338, pp.1654~1660 (2005)
61. Zhou G, "Perspectives on therapeutic neutralizing antibodies against the novel Coronavirus SARS-CoV-2", Int. J. Biol. Sci, 16, pp.1718~1723 (2020)
62. Mubarak A, "Middle East Respiratory Syndrome Coronavirus(MERS-CoV) : infection, immunological response, and vaccine development", J. Immunol. Res, 2019, pp.6491738~ (2019)
63. Coleman CM, "Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice", Vaccine, 32, pp.3169~3174 (2014)
64. Payne DC, "Persistence of antibodies against Middle East Respiratory Syndrome Coronavirus", Emerg. Infect. Dis, 22, pp.1824~1826 (2016)
65. Liu W, "Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome", J. Infect. Dis, 193, pp.792~795 (2006)
66. Tang F, "Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome : a six-year follow-up study", J. Immunol, 186, pp.7264~7268 (2011)
67. Zhang B, "Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19", Front. Mol. Biosci, 7, pp.157~ (2020)
68. Haveri A, "Serological and molecular findings during SARSCoV-2 infection : the first case study in Finland, January to February 2020", Euro Surveill, 25, pp.2000266~ (2020)
69. Liu L, "Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection", JCI Insight, 4, pp.e123158~ (2019)

관련 논문AI추천